Osmol Therapeutics

OSM-0205 is preparing to enter the clinic by the end of 2024. We've been developing OSM-0205 to address the urgent needs of patients faced with the challenges of chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Find CEO Bob Linke in Stockholm on November 5 at 10 AM as he presents at #BioEurope, celebrating 30 years of facilitating partnerships to keep biotech moving forward. https://bit.ly/3zwlNKF #healthcare #BreastCancerAwarenessMonth

Osmol wants to ease the patient cancer journey. Currently, there are no treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) for breast cancer patients undergoing taxane-based chemotherapy. The only available options are to either delay or lower the dose, potentially impacting quality of care. On Tuesday, October 29 at 11AM ET, Bob Linke, CEO, will present at Demy-Colton #BioFuture2024 with other executives looking to shape the future of healthcare as OSM-0205 prepares to enter the clinic by the end of 2024. We're hopeful that our lead candidate, OSM-0205, can change the future of cancer care and give patients a leg up on this critical challenge in breast cancer treatment. https://bit.ly/3Y1WgCl #biotechnology #BreastCancerAwarenessMonth

Early detection is crucial in the fight against breast cancer. While mammograms help save lives through early diagnosis, important treatments like chemotherapy remain essential to improve the prognosis for many patients. At Osmol Therapeutics, we are committed to ensuring that patients not only survive but thrive by advancing innovative therapies like OSM-0205, designed to protect against the neurotoxic side effects of the taxane-based chemotherapy treatments often used in breast cancer care. Learn more about the importance of early detection with National Breast Cancer Foundation, Inc.: https://bit.ly/3XMv2hQ #innovation #BreastCancerAwarenessMonth #NationalMammographyDay

Today is Metastatic Breast Cancer Awareness Day, a moment to honor the strength of those living with metastatic breast cancer (MBC) and reflect on the urgent need for innovation in treatment. Osmol stands with the MBC community today and every day in the fight for better outcomes with our groundbreaking research. Our lead candidate, OSM-0205, is designed to protect these patients undergoing taxane-based chemotherapies from: -      chemotherapy-induced peripheral neuropathy (CIPN) -      chemotherapy-induced cognitive impairment (CICI) Learn more about the peripheral neuropathy and cognitive impairment (a.k.a. “chemo brain”) often associated with taxane-based breast cancer treatments via Breastcancer.org: CIPN: https://bit.ly/4epdfEx CICI: https://bit.ly/3BrElME #BreastCancerAwarenessMonth #drugdevelopment #healthcare

The Biotechnology Innovation Organization Investor Forum comes at an important time for Osmol as OSM-0205 prepares to enter the clinic later this year. Our groundbreaking approach aims to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) before they impact patients – easing their journey. Many thanks to our CEO, Bob Linke, for presenting on behalf of Osmol on October 16 at 11:15 AM PT. https://bit.ly/3TRYpOq #BIF24 #investing #BreastCancerAwarenessMonth

Osmol is committed to not only fighting cancer but also improving the quality of life for those undergoing chemotherapy. With a dual focus on physical and cognitive well-being, our preclinical studies reveal a promising path. Our lead candidate, OSM-0205, is specifically designed to protect against the debilitating side effects of taxane-based chemotherapy treatments commonly used to treat breast cancer. Watch this video to learn more about how we are working to improve the treatment experience for breast cancer patients. Visit our website: https://bit.ly/4emvR80 #BreastCancerAwarenessMonth #CancerResearch #drugdevelopment

According to the National Breast Cancer Foundation, Inc., approximately 30% of all new cancer diagnoses in women will be breast cancer, and there are over 4 million breast cancer survivors in the U.S. Even with tremendous advancements in care, many breast cancer patients face challenging side effects from their treatment, including chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), which can negatively affect their care and impact their quality of life. Osmol is preparing to advance OSM-0205, our lead candidate, into the clinic by year's end for the treatment and prevention of CIPN and CICI – paving the way for optimal chemotherapy dosing and enhanced patient outcomes. Learn more about how patients can manage their chemotherapy side effects: https://bit.ly/3Y6Vx31 #BreastCancerAwarenessMonth #healthcare #biotechnology

Going through breast cancer treatment is difficult enough for patients. Facing a choice between inadequate cancer treatment and the debilitating effects of chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) is not something that patients should have to experience. Unfortunately, that's the reality for nearly 80% of breast cancer patients receiving taxane-based chemotherapies. There are no effective treatments for CIPN or CICI. Learn how Osmol is facing this critical challenge in cancer treatment, aiming to prevent these conditions before they impact patients with OSM-205, which is on track to begin clinical trials by the end of this year: https://bit.ly/3XhXDvg #oncology #drugdevelopment #biopharma

Our CEO, Bob Linke, is in Boston for a company presentation and business update at LSX USA Congress at 3pm ET on Wednesday, September 11th. We are thankful for Bob's ongoing leadership as our lead candidate, OSM-205, for the preventative treatment of chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) prepares to enter the clinic before the end of the year. #LSXUSA #healthcare #BiotechLeaders

🎥 Watch our latest video that dives into the problem of chemotherapy-induced peripheral neuropathy (CIPN). We're excited about OSM-205's potential to protect neurons in both the peripheral and central nervous systems; this would help patients of taxane-based chemotherapies avoid having to choose between inadequate cancer treatment and the debilitating effects of CIPN. With OSM-205 preparing to enter the clinic later this year, Osmol strives to ensure patients get the best care without painful side effects. https://bit.ly/4fxk47V #drugdevelopment #breastcancer #biopharma Bob Linke